¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"primed lymphocyte"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® lymphocyte ÇÑ±Û ¸²ÇÁ±¸
¼³¸í   
  ¸é¿ª±â´ÉÀ» ´ã´çÇϴ ¼¼Æ÷. °ñ¼ö¿¡¼­ ¸¸µé¾îÁö¸ç, ¸²ÇÁ±¸´Â Å©°Ô 2°¡Áö·Î ´ëºÐµÈ´Ù. À̸¥¹Ù T¸²ÇÁ¼¼Æ÷, B¸²ÇÁ¼¼Æ÷·Î ³ª´µ¾îÁö°Ô µÈ´Ù. T¸²ÇÁ¼¼Æ÷´Â ¼¼Æ÷¼º¸é¿ª¿¡ °ü¿©Çϸç, ÁַΠ¹ÙÀÌ·¯½ºº´¿¡ ´ëÇÑ ¸é¿ª±â´ÉÀ̳ª, ¾Ë·¹¸£±â(¸é¿ª¹ÝÀÀ 4¹øÇü µî) µî¿¡ °ü¿©ÇÑ´Ù. ÀÌ¿¡ ºñÇØ B¸²ÇÁ¼¼Æ÷´Â Ã¼¾×¼º¸é¿ª¿¡ °ü¿©ÇÏ¿©, Ç׿ø Ç×ü ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â Ç×ü¸¦ »ý»êÇϰí ÁַΠ¼¼±Õ°¨¿°¿¡ ´ëÇÑ ¸é¿ª±â´ÉÀ» ´ã´çÇÑ´Ù.
¿µ¹® T-lymphocyte ÇÑ±Û Æ¼ ¸²ÇÁ±¸
¼³¸í   
  ¸²ÇÁ°è¼¼Æ÷(¸²ÇÁ±¸)´Â Å©°Ô 2°¡Áö·Î ´ëºÐµÈ´Ù. À̸¥¹Ù T¸²ÇÁ¼¼Æ÷(T-cell), B¸²ÇÁ¼¼Æ÷(B-cell)·Î ³ª´µ¾îÁø´Ù. T¸²ÇÁ¼¼Æ÷´Â ¼¼Æ÷¼º ¸é¿ª¿¡ °ü¿©Çϸç, ÁַΠ¹ÙÀÌ·¯½ºº´¿¡ ´ëÇÑ ¸é¿ª±â´ÉÀ̳ª, ¾Ë·¹¸£±â µî¿¡ °ü¿©ÇÑ´Ù. ÀÌ¿¡ ºñÇØ B¸²ÇÁ¼¼Æ÷´Â Ã¼¾×¼º ¸é¿ª¿¡ °ü¿©ÇÏ¿©, Ç׿ø Ç×ü ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â Ç×ü¸¦ »ý»êÇϰí ÁַΠ¼¼±Õ¼º Áúȯ¿¡ ´ëÇÑ ¸é¿ª ±â´ÉÀ» ´ã´çÇÑ´Ù. T-¸²ÇÁ±¸´Â ¸é¿ª±â´É¿¡ °¡Àå Áß¿äÇÑ ¿ªÇÒÀ» Çϴ ¼¼Æ÷·Î¼­ ¼¼Æ÷¸é¿ªÀ» ´ã´çÇϸç B-cellÀÇ ÀÛ¿ëÀ» Á¶ÀýÇϴ ±â´Éµµ ÀÖ´Ù. °ñ¼ö¿¡¼­ »ý¼ºµÇ¾î °¡½¿»ù¿¡¼­ ¼º¼÷µÈ´Ù. Å©°Ô º¸Á¶T¼¼Æ÷(helper T-cell: ¸é¿ªÀÛ¿ëÀÇ ¹ß»ýÀ» º¸Á¶ÇÑ´Ù)¿Í T¼¼Æ÷(suppressor T-cell: ¸é¿ªÀÛ¿ëÀÇ ¹ß»ýÀ» ¾ïÁ¦ÇÑ´Ù)·Î ±¸ºÐµÇ¸ç À̵éÀº ¼¼Æ÷ Ç¥¸é¿¡ ºÐÆ÷Çϴ Ç׿ø¿¡ ÀÇÇØ¼­ ½Äº°µÉ ¼ö ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • primed lymphocyte
    ÃÊȸ¹Î°¨¸²ÇÁ±¸
  • primed lymphocyte typing
    ÃÊȸ¹Î°¨¸²ÇÁ±¸Çü°áÁ¤
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • primed cell
    ÃÊȸ¹Î°¨¼¼Æ÷
  • atypical lymphocyte
    ºñÁ¤Çü¸²ÇÁ±¸
  • effector lymphocyte
    È¿°ú¸²ÇÁ±¸
  • killer lymphocyte
    »ìÇØ¸²ÇÁ±¸, ¼¼Æ÷µ¶¼º¸²ÇÁ±¸
  • lymphocyte
    ¸²ÇÁ±¸
  • lymphocyte activating factor
    ¸²ÇÁ±¸È°¼ºÀÎÀÚ
  • lymphocyte inhibitory factor
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
  • lymphocyte series
    ¸²ÇÁ±¸°è¿­
  • lymphocyte-activating determinant
    ¸²ÇÁ±¸È°¼º°áÁ¤ÀÎÀÚ
  • mixed lymphocyte culture
    È¥ÇÕ¸²ÇÁ±¸¹è¾ç
  • mixed lymphocyte culture test
    È¥ÇÕ¸²ÇÁ±¸¹è¾ç°Ë»ç
  • mixed lymphocyte reaction
    ¸²ÇÁ±¸È¥ÇÕ¹è¾ç¹ÝÀÀ
  • monocyte lymphocyte ratio
    ´ÜÇÙ±¸¸²ÇÁ±¸ºñÀ²
  • reticular lymphocyte
    ±×¹°¸²ÇÁ±¸, ¸Á»ó¸²ÇÁ±¸
  • sensitized lymphocyte
    ¹Î°¨È­¸²ÇÁ±¸
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • mixed lymphocyte culture
    È¥ÇÕ¸²ÇÁ±¸¹è¾ç
  • lymphocyte
    ¸²ÇÁ±¸
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • primed lymphocyte
    ÃÊȸ¹Î°¨¸²ÇÁ±¸
  • primed lymphocyte typing
    ÃÊȸÇ׿øÀÚ±ØÈĸ²ÇÁ±¸Çüº°È­
  • primed lymphocyte-typing test
    °¨ÀÛ¸²ÇÁ±¸Çüº°°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • primed cell
    ÃÊȸ°¨ÀÛ¼¼Æ÷
  • atypical lymphocyte
    ºñÀüÇü¸²ÇÁ±¸
  • lymphocyte-activating determinant
    ¸²ÇÁ±¸È°¼º°áÁ¤±â
  • effector lymphocyte
    ÀÛµ¿¸²ÇÁ±¸
  • lymphocyte activating factor
    ¸²ÇÁ±¸È°¼ºÀÎÀÚ
  • lymphocyte inhibitory factor
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
  • killer lymphocyte
    ¼¼Æ÷µ¶¼º¸²ÇÁ±¸
  • lymphocyte
    ¸²ÇÁ±¸
  • leukocytoid lymphocyte
    ¹éÇ÷±¸¸ð¾ç¸²ÇÁ±¸
  • lymphocyte series
    ¸²ÇÁ±¸°è¿­
  • resident lymphocyte
    »óÁÖ¸²ÇÁ±¸
  • reticular lymphocyte
    ¸Á»ó¸²ÇÁ±¸
  • sensitized lymphocyte
    ¹Î°¨¸²ÇÁ±¸
  • short lived lymphocyte
    ´Ü»ý¸²ÇÁ±¸, ªÀº¼ö¸í¸²ÇÁ±¸
  • thymic lymphocyte
    °¡½¿»ù¸²ÇÁ±¸
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • primed lymphocyte
    ÃÊȸ°¨ÀÛ ¸²ÇÁ±¸
  • primed lymphocyte typing
    ÃÊȸÇ׿øÀÚ±ØÈÄ ¸²ÇÁ±¸Çüº°È­
  • primed lymphocyte-typing test
    ÃÊȸ°¨ÀÛ ¸²ÇÁ±¸ÀÌ¿ë Çüº°°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • T cell ; T lymphocyte ; thymus derived lymphocyte
    T¼¼Æ÷ ; T¸²ÇÁ? ; Èä¼±À¯·¡¸²ÇÁ?
  • primed
    ÃÊȸ°¨ÀÛ[µÈ]
  • primed
    ÃÊȸÇ׿øÀÚ±Ø(ôøüÞù÷ê«ô§Ð½)À» ¹ÞÀº.
  • primed
    ÃÊȸÇ׿øÀÚ±Ø(ôøüÞù÷ê«í©Ð½)À» ¹ÞÀº
  • primed T cell
    ÃÊȸ°¨ÀÛ T¼¼Æ÷
  • B cell/lymphocyte
    B ¼¼Æ÷/¸²ÇÁ±¸
  • B lymphocyte
    B ¸²ÇÁ±¸
  • B-lymphocyte
    B ¸²ÇÁ±¸.
  • Bare lymphocyte syndrome
    ¹«Ç¥Áö¸²ÇÁ±¸ÁõÈıº
  • T cell/lymphocyte
    T ¼¼Æ÷/¸²ÇÁ±¸
  • T lymphocyte
    T ¸²ÇÁ±¸
  • T-lymphocyte
    T-Àӯı¸
  • anti-lymphocyte globulin
    ¸²ÇÁ±¸ Çױ۷κҸ°
  • antigen, lymphocyte defined (LD)
    ¸²ÇÁ±¸ Ç¥¸éÇ׿ø, LDÇ׿ø
  • granulocyte-monocyte-lymphocyte antigens
    °ú¸³±¸´Ü±¸¸²ÇÁ±¸Ç׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • primed lymphocyte
    ÃÊȸ°¨ÀÛ ¸²ÇÁ±¸
  • primed lymphocyte typing
    ÃÊȸÇ׿øÀÚ±ØÈÄ ¸²ÇÁ±¸Çüº°È­
  • primed lymphocyte-typing test
    ÃÊȸ°¨ÀÛ ¸²ÇÁ±¸ÀÌ¿ë Çüº°°Ë»ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cell, primed T
    ÃÊȸ°¨ÀÛ T¼¼Æ÷
  • leader RNA primed transcription
    ¼±µµ RNA ½Ã¹ßÀü»ç
  • primed
    ÃÊȸÇ׿øÀÚ±Ø(ôøüÞù÷ê«ô§Ð½)À» ¹ÞÀº.
  • primed
    ÃÊȸÇ׿øÀÚ±Ø(ôøüÞù÷ê«í©Ð½)À» ¹ÞÀº
  • primed
    ÃÊȸ°¨ÀÛ[µÈ]
  • primed T cell
    ÃÊȸ°¨ÀÛ T¼¼Æ÷
  • anti-lymphocyte globulin
    ¸²ÇÁ±¸ Çױ۷κҸ°
  • antigen, lymphocyte defined (LD)
    ¸²ÇÁ±¸ Ç¥¸éÇ׿ø, LDÇ׿ø
  • atypical lymphocyte
    ÀÌÇü<ºñÁ¤Çü>¸²ÇÁ±¸(?Ë´).
  • cytotoxic T lymphocyte (CTL)
    ¼¼Æ÷µ¶¼ºT¸²ÇÁ±¸
  • effector T lymphocyte
    ÀÛµ¿T¸²ÇÁ±¸
  • effector lymphocyte
    ÀÛµ¿¸²ÇÁ±¸.
  • granulocyte-monocyte-lymphocyte antigens
    °ú¸³±¸´Ü±¸¸²ÇÁ±¸Ç׿ø
  • granulocyte-platelet-lymphocyte antigens
    °ú¸³±¸Ç÷¼ÒÆÇ¸²ÇÁ±¸Ç׿ø
  • hodgkins disease,lymphocyte predominance
    ¸²ÇÁ±¸ ÇöÀúÇü
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Small lymphocyte
    ÀÛÀº¸²ÇÁ±¸
    [¿¾ ¿ë¾î] ¼ÒÀӯı¸
  • Large lymphocyte
    Å«¸²ÇÁ±¸
    [¿¾ ¿ë¾î] ´ëÀӯı¸
  • Medium-sized lymphocyte
    Áß°£¸²ÇÁ±¸
    [¿¾ ¿ë¾î] ÁßÀӯı¸
  • Lymphocyte
    ¸²ÇÁ±¸
    [¿¾ ¿ë¾î] Àӯı¸
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • primed cell
    °¨ÀÛ¼¼Æ÷(ÊïíÂá¬øà)
  • primed synthesis method
    ±âÆø ÇÕ¼º¹ý(ÑÃøïùêà÷Ûö)
  • lymphocyte-derived chemotactic factor
    ¸²ÇÁ±¸-À¯µµ(ë¯Óô) È­ÇÐÁÖ¼ºÀÎÀÚ(ûùùÊñËà÷ì×í­)
  • lymphocyte transformation
    ¸²ÇÁ±¸º¯Çü(ܨû¡)
  • mixed lymphocyte culture
    È¥ÇÕ(ûèùê)¸²ÆÄ±¸¹è¾ç(ÛÆå×)
  • small lymphocyte
    ¼Ò(á³)Àӯı¸
  • T lymphocyte
    T Àӯı¸
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lymphocyte
    ¸²ÇÁ±¸
  • T cell ¡ìthymus derived lymphocyte¡í
    T¼¼Æ÷ ¡ì Èä¼±À¯·¡ ¸²ÇÁ±¸¡í
  • T lymphocyte
    T¸²ÇÁ±¸
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
PLT pancreatic lymphocytic infiltration; platelet; primed lymphocyte test; primed lymphocyte typing; psi...
PLT Primed Lymphocyte Typing
MORAC mixed oligonucleotides primed amplification of complementary deoxyribonucleic acid
CTL cervico-thoraco-lumbar; control; cytolytic C lymphocyte; cytotoxic T-lymphocyte
HLA-LD human lymphocyte antigen-lymphocyte defined
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
PLT Primed Lymphocyte Test
PLT Primed Lymphocyte Typing
AP-PCR Arbitrarily Primed PCR
AP Arbitrarily primed
AP-PCR Arbitrarily primed Polymerase Chain Reaction
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • primed
    ÃÊȸ Ç׿ø ÀÚ±ØÀ» ¹ÞÀº
    ÃÖÃÊÀÇ Ç׿ø ÀÚ±ØÀ» ¹ÞÀº °á°ú ¸é¿ªÇÐÀûÀ¸·Î Ȱ¼ºÈ­ÇÏ´Â. ¸é¿ª°èÀÇ ¼¼Æ÷¿¡ °üÇÏ¿© »ç¿ëµÇ´Â ¿ë¾î.
  • B lymphocyte
    B ¸²ÇÁ±¸
    1. Èä¼± ºñÀÇÁ¸¼ºÀ¸·Î Èä¼±ÀÇ ¿µÇâÀ» ¹ÞÁö ¾Ê°í, Á¶Á÷À» À¯ÁÖÇÏ´Â ¸²ÇÁ±¸. ü¾×¼º ¸é¿ª¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, Ç׿ø¿¡ ÀÇÇÑ ÀÚ±ØÀ¸·Î ¾×¼º Ç×ü¸¦ ÇÕ¼ºÇÏ´Â ÇüÁú±¸·Î µÈ´Ù. 2. Ç÷¾×, °ñ¼ö ¹× ¸²ÇÁÀý, ºñÀå, Æíµµ µî ¸²ÇÁÁ¶Á÷, ±×¸®°í ¼ÒÈ­°ü°è µîÀÇ ºñ¸²ÇÁ Á¶Á÷¿¡ ºÐÆ÷ÇÑ´Ù. ÀÎü Ç÷¾×ÀÇ 10-20% Â÷ÁöÇÑ´Ù. Ç׿ø µî¿¡ ÀÇÇØ Ȱ¼ºÈ­µÇ¸é ¸²ÇÁ¿©Æ÷ ³»¿¡¼­ ¸ð¼¼Æ÷ º¯È¯
  • B-lymphocyte
    B ¸²ÇÁ±¸
    Ç÷Áß Àӯı¸ÀÇ 5-15%¸¦ Â÷ÁöÇÏ¸ç ¼¼Æ÷ Ç¥¸é¿¡ ¸é¿ª ±Û·ÎºÎ¸°ÀÌ Á¸ÀçÇÑ´Ù. ÀÌµé ¸é¿ª ±Û·ÎºÎ¸°Àº Ç׿ø¿¡ ´ëÇÑ ¼ö¿ëü·Î ÀÛ¿ëÇÑ´Ù. Ç÷Áß B ¼¼Æ÷ÀÇ ´ëºÎºÐÀº Ç¥¸é¿¡ IgM°ú IgD¸¦ °®°í ÀÖÀ¸¸ç ¼Ò¼ö¿¡¼­ IgG, IgA ȤÀº IgE°¡ ¹ß°ßµÈ´Ù. ±×·¯³ª Á¡¸· µî¿¡¼­´Â IgA¸¦ °®°í ÀÖ´Â B¼¼Æ÷°¡ ¸¹ÀÌ ¹ß°ßµÈ´Ù.
  • bone marrow-derived lymphocyte
    °ñ¼ö À¯·¡ Àӯı¸
  • bursa-derived lymphocyte
    ÆÄºÎ¸®½Ã¿ì½º ³¶ À¯·¡ Àӯı¸
  • effector lymphocyte
    ÀÛµ¿ ¸²ÇÁ±¸
  • immunocompetent T lymphocyte
    ¸é¿ª Àû°Ý T Àӯı¸
  • lymphocyte
    Àӯı¸
  • lymphocyte defined antigen
    ¸²ÇÁ±¸ ±ÔÁ¤ Ç׿ø
  • lymphocyte migration
    Àӯı¸ À̵¿
  • marrow lymphocyte
    °ñ¼ö ¸²ÇÁ±¸
  • mixed lymphocyte culture
    È¥ÇÕ ¸²ÇÁ±¸ ¹è¾ç
  • monocyte lymphocyte ratio
    ´Ü±¸ ¸²ÇÁ±¸ºñ
  • small lymphocyte
    ÀÛÀº ¸²ÇÁ±¸, ¼Ò¸²ÇÁ±¸
  • thymus-derived lymphocyte
    Èä¼± À¯·¡ Àӯı¸
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
lymphocyte lymphocyte A type of non-granular antibodies.
(09 Oct 1997)
antigens, differentiation, b-lymphocyte Membrane antigens associated with maturation stages of B-lymphocytes, often expressed in tumours of B-cell origin.
(12 Dec 1998)
antigens, differentiation, t-lymphocyte Antigens expressed on the cell membrane of T-lymphocytes during differentiation, activation, and normal and neoplastic transformation. Their phenotypic characterization is important in differential diagnosis and studies of thymic ontogeny and T-cell function.
(12 Dec 1998)
bare lymphocyte syndrome <syndrome> Absence of HLA antigens on peripheral mononuclear cells, which may result in immunodeficiency.
(05 Mar 2000)
B lymphocyte <haematology, immunology> An immunologically important lymphocyte, produced by the bone marrow, that is responsible for the production of immunoglobulins, it is the precursor of the plasma cell.
The surface markers can be used to detect and differentiate chronic lymphocytic leukaemia from acute lymphocytic leukaemia.
(13 Nov 1997)
b-lymphocyte subsets A classification of B-lymphocytes based on structurally or functionally different populations of cells.
(12 Dec 1998)
gene rearrangement, b-lymphocyte Ordered rearrangement of b-lymphocyte variable gene regions coding for the immunoglobulin chains, thereby contributing to antibody diversity. It occurs during the differentiation of the immature b-lymphocyte.
(12 Dec 1998)
gene rearrangement, b-lymphocyte, heavy chain Ordered rearrangement of b-lymphocyte variable gene regions thereby contributing to antibody diversity. It occurs during the first stage of differentiation of the immature b-lymphocyte.
(12 Dec 1998)
gene rearrangement, b-lymphocyte, light chain Ordered rearrangement of b-lymphocyte variable gene regions coding for the kappa or lambda light chains, thereby contributing to antibody diversity. It occurs during the second stage of differentiation of the immature b-lymphocyte.
(12 Dec 1998)
gene rearrangement, t-lymphocyte Ordered rearrangement of T-cell variable gene regions coding for the antigen receptors.
(12 Dec 1998)
receptors, lymphocyte homing Cell surface glycoproteins on lymphocytes and other leukocytes that mediate adhesion to specialised blood vessels called high endothelial venules. Several different classes of lymphocyte homing receptors have been identified, and they appear to target different surface molecules (addressins) on high endothelial venules in different tissues. The adhesion plays a crucial role in the trafficking of lymphocytes.
(12 Dec 1998)
virgin lymphocyte <haematology, immunology> A lymphocyte that has not and whose precursors have not, encountered the antigenic determinant for which it possesses receptors.
(18 Nov 1997)
CD4 lymphocyte A specific type of lymphocyte, derived from the thymus gland, that plays an important role in cellular immunity. T4 lymphocytes (CD4 cells) are decreased (absolute counts less than 200) in patients with AIDS resulting in compromised immune function.
(27 Sep 1997)
CD4 lymphocyte count A count of the number of CD4-positive lymphocytes in the blood. Determination requires the use of a fluorescence-activated flow cytometer.
(12 Dec 1998)
Rieder's lymphocyte An abnormal form of lymphocyte that has a greatly indented (or lobed), slightly twisted nucleus; such cells are usually observed in certain examples of chronic lymphocytic leukaemia.
(05 Mar 2000)
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
primed lymphocyte t. a technique used for typing of Class II HLA antigens: unknown cells are exposed to a panel of lymphocytes primed against specific HLA antigens by prior coculture with stimulator cells that matched the primed cells at all but one HLA locus; when restimulated by the same HLA antigen the primed cells give a secondary proliferative response, which shows that the unknown cells bear the same antigen as the stimulator cells.
Ãâó: www.mercksource.com/pp/us/cns/cns_health_library.j...
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lymphocyte
    ¸²ÇÁÅç(¼¼Æ÷)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á